Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.69 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610372 | 0.89 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL1401249 | 0.89 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL1400972 | 0.89 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL1400971 | 0.89 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL4819222 | 0.88 | TACR1 (0.68) | TACR1TACR3CCR2 | |
| SCHEMBL1400874 | 0.88 | TACR1 (0.68) | TACR1TACR3USP2 | |
| SCHEMBL13980761 | 0.88 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL4819217 | 0.88 | TACR1 (0.68) | TACR1TACR3CCR2 | |
| SCHEMBL1400878 | 0.88 | TACR1 (0.68) | TACR1TACR3USP2 | |
| SCHEMBL14017628 | 0.88 | TACR1 (0.68) | TACR1TACR3CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-8138334-B2 | Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-1874783-B1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292228-A1 | SUBSTITUTED OXA-DIAZA-SPIRO-[5.5]-UNDECANONE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | NPSR1, OPRK1, PROKR2 | TACR1 79/4885TACR3 189/4885KCNH2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.